Shree Mulay, MD
Nephrology · Dyersburg, TNNPI 1548671845
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,910 of the $55,625 with a category attached, or 75.3%. 27 manufacturers reported payments, led by Amgen at 55.2% of the total. 2025 is the largest year on record at $21,251, more than ten times the $292 reported in 2019. Among nephrology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $200.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$31K
- Scpharmaceuticals Inc.$15K
- Daxor Corporation$3K
- Bayer$2K
- Nuwellis, Inc.$1K
- AstraZeneca$752
- plus $4K from 21 others
Across 5 payments — averaging $30,082 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nuwellis, Inc.$150K
What the payments were for
- Consulting fees$1,5003%
- Speaking & faculty fees$41,91075%
- Travel & lodging$2,3014%
- Food & beverage$9,48417%
- Education$4311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 68 | $30,707 |
| Scpharmaceuticals Inc. | 7 | $14,985 |
| Daxor Corporation | 8 | $2,723 |
| Bayer | 52 | $1,564 |
| Nuwellis, Inc. | 21 | $1,257 |
| AstraZeneca | 18 | $752 |
| Otsuka America Pharmaceutical, Inc. | 18 | $698 |
| Renalytix AI, Inc. | 6 | $303 |
| Ardelyx, Inc. | 6 | $294 |
| Calliditas Therapeutics US Inc. | 6 | $275 |
| Akebia Therapeutics Inc | 6 | $257 |
| Fresenius USA Marketing, Inc. | 9 | $248 |
| Travere Therapeutics, Inc. | 12 | $243 |
| Novartis | 8 | $213 |
| Edwards Lifesciences | 2 | $160 |
| Abiomed | 1 | $149 |
| Vifor Pharma, Inc. | 5 | $136 |
| GSK | 7 | $120 |
| OPKO Pharmaceuticals, LLC | 5 | $108 |
| Boehringer Ingelheim | 4 | $83 |
| Bard Peripheral Vascular, Inc. | 1 | $78 |
| Novo Nordisk | 1 | $72 |
| Baxter Healthcare | 1 | $68 |
| Nxstage Medical, Inc. | 1 | $65 |
| Merck | 2 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$28,447
- FUROSCIX$14,897
- BVA-100$2,525
- Kerendia$842
- AQUADEX SMARTFLOW CONSOLE$593
- FARXIGA$443
- JYNARQUE$325
- AURYXIA$164
- Impella$149
- HemoSphere$139
- XPHOZAH 30 MG$125
- TARPEYO$123
- Velphoro$111
- LOKELMA$108
- KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT$101
How this compares
$55,625 in reported general payments places this provider in the 95th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 87 | $2,510,355 |
| VelphoroSucroferric Oxyhydroxide | 107 | $255,592 |
| JynarqueTolvaptan | 12 | $237,241 |
| FarxigaDapagliflozin Propanediol | 245 | $203,580 |
| KerendiaFinerenone | 113 | $123,619 |
| EntrestoSacubitril/Valsartan | 140 | $116,341 |
| XphozahTenapanor Hcl | 26 | $110,489 |
| JardianceEmpagliflozin | 97 | $67,926 |
| VeltassaPatiromer Calcium Sorbitex | 75 | $61,196 |
| AuryxiaFerric Citrate | 35 | $56,034 |
| RayaldeeCalcifediol | 29 | $50,861 |
| Sevelamer Carbonate | 308 | $36,802 |
| LokelmaSodium Zirconium Cyclosilicate | 49 | $36,100 |
| Calcium Acetate | 235 | $14,864 |
| Nifedipine ErNifedipine | 266 | $5,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $30,707 | $2,510,35587 claims |
| Fresenius USA Marketing, Inc.Velphoro | $248 | $255,592107 claims |
| AstraZenecaFarxiga, Lokelma | $752 | $239,680294 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $698 | $237,24112 claims |
| BayerKerendia | $1,564 | $123,619113 claims |
| NovartisEntresto | $213 | $116,341140 claims |
| Boehringer IngelheimJardiance | $83 | $67,92697 claims |
| Akebia Therapeutics IncAuryxia | $257 | $56,03435 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $108 | $50,86129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Dyersburg
- Jamie DwyerNashville$461K
- Ross NesbitKnoxville$452K
- Gerald BorrelliKnoxville$190K
- Volker HaaseNashville$123K
- Chike NzerueCookeville$95K
- Talat IkizlerNashville$93K
- Omar HamzeMemphis$90K
- Julia LewisNashville$87K
- Osama El ShamyNashville$87K
- Omar DavisMemphis$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.